Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 6/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7053255 | 0.89 | MPO (0.55) | MPOKMT2AKDM4EMEN1MAPT | |
| SCHEMBL26173841 | 0.87 | MPO (0.49) | MPOKMT2AKDM4EMEN1NR4A2 | |
| SCHEMBL3469723 | 0.85 | KMT2A (0.58) | KMT2AKDM4EMEN1MAPTALDH1A1 | |
| SCHEMBL7055279 | 0.83 | MPO (0.55) | MPOKMT2AKDM4EMEN1MAPT | |
| SCHEMBL24029264 | 0.83 | MPO (0.55) | MPOKMT2AKDM4EMEN1MAPT | |
| SCHEMBL7056204 | 0.81 | LMNA (0.50) | KMT2AKDM4EMEN1MAPTALDH1A1 | |
| SCHEMBL2459826 | 0.81 | NPSR1 (0.61) | MPOKMT2AKDM4EMEN1MAPT | |
| SCHEMBL31320223 | 0.81 | NPSR1 (0.61) | MPOKMT2AKDM4EMEN1MAPT | |
| SCHEMBL7058413 | 0.81 | KMT2A (0.43) | MPOKMT2AKDM4EMEN1MAPT | |
| SCHEMBL7054202 | 0.81 | KMT2A (0.43) | KMT2AKDM4EMEN1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183187-A1 | QUINAZOLINE COMPOUNDS AS INHIBITORS OF PREMATURE TERMINATION CODONS | CENTRE NAT RECH SCIENT (FR) | 2023-06-15 | — | — | US | disclosed |
| US-20230183187-A1 | QUINAZOLINE COMPOUNDS AS INHIBITORS OF PREMATURE TERMINATION CODONS | CENTRE NAT RECH SCIENT (FR) | 2023-06-15 | — | — | US | disclosed |
| WO-2021228945-A1 | QUINAZOLINE COMPOUNDS AS INHIBITORS OF PREMATURE TERMINATION CODONS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183187-A1 | QUINAZOLINE COMPOUNDS AS INHIBITORS OF PREMATURE TERMINATION CODONS | UPF1, NUDT21, REV1 | MPO 4481/4885KMT2A 2885/4885KDM4E 2993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.